NCT01419691View on ClinicalTrials.gov

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic LymphomaLeukemia, Prolymphocytic
Interventions
DRUG

auranofin

6 mg twice a day for a total of 12 mg total daily dose

Trial Locations (1)

66205

University of Kansas Cancer Center, Westwood

Sponsors
All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Kansas Bioscience Authority

UNKNOWN

collaborator

Therapeutics for Rare and Neglected Diseases (TRND)

NIH

lead

University of Kansas Medical Center

OTHER

NCT01419691 - Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter